Recombinant Human Tnf Receptor-Associated Factor 6 (TRAF6)

Name: Recombinant Human Tnf Receptor-Associated Factor 6 (TRAF6)
Brand: Beta LifeScience
SKU: BLC-06149P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tnf Receptor-Associated Factor 6 (TRAF6) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	Q9Y4K3
Target Symbol	TRAF6
Synonyms	E3 ubiquitin-protein ligase TRAF6; Interleukin 1 signal transducer; Interleukin-1 signal transducer; MGC 3310; MGC:3310; MGC3310; OTTHUMP00000232772; OTTHUMP00000232773; RING finger protein 85; RNF 85; RNF85; TNF receptor associated factor 6; TNF receptor-associated factor 6; TNF receptor-associated factor 6; E3 ubiquitin protein ligase; TRAF 6; Traf6; TRAF6_HUMAN
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Target Protein Sequence	MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV
Expression Range	1-522aa
Protein Length	Full Length
Mol. Weight	59.6 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2. Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production.
Subcellular Location	Cytoplasm. Cytoplasm, cell cortex. Nucleus. Lipid droplet.
Protein Families	TNF receptor-associated factor family, A subfamily
Database References	HGNC: 12036 OMIM: 602355 KEGG: hsa:7189 STRING: 9606.ENSP00000337853 UniGene: PMID: 30224945 TRAF6 can promote the proliferation of stromal cells of benign prostatic hyperplasia via Akt/mTOR signaling. PMID: 29171041 Study identified IRAK1 and TRAF6 are direct targets of miR-146a in cervical cancer cells. Their expression is downregulated by miR-146a to promote cell viability. PMID: 29693168 Immune profiling of human prostate epithelial cells in health and pathology determined by expression of p38/TRAF-6/ERK MAP kinases pathways has been reported. PMID: 29475459 Downregulation of miR-124 in human osteosarcoma tissues and cell lines may increase the expression of TRAF6 protein. miR-124 may inhibit cell cycle progression and invasion of osteosarcoma cells, and promote apoptosis by regulating TRAF6. PMID: 29436576 Low TRAF6 expression is associated with posterior longitudinal ligament ossification. PMID: 29782494 these results suggest that miR-146a-5p affects proliferation and apoptosis in a cellular context-dependent manner and selectively disarms the TRAF6-mediated branch of the TGF-beta signaling in oral squamous cell carcinoma cell lines by sparing Smad4 involvement PMID: 29048658 MALT1 and TRAF6 cooperatively interact with CARMA1-BCL10 filaments and form CARMA1-BCL10-MALT1-TRAF6 signalosome. PMID: 29382759 our data demonstrated that miR146b5p, as a tumor suppressor, mediated temozolomide resistance in GBM cells through negatively regulating TRAF6 expression, indicating that miR146b5p and its targeted genes would be potential therapeutic targets for glioma therapy. PMID: 29048680 genetic association studies in Han population in southern China: Data suggest that, in subjects with type 2 diabetes, an SNP in NLRX1 (rs4245191) is associated with macro-vascular complications and cerebral infarction in the population studied; no such association was found for two other SNPs in NLRX1 (rs10790286, rs561830) or for two SNPs in TRAF6 (rs5030445, rs16928973). (NLRX1 = NLR family member-X1) PMID: 29046236 protein-protein interaction studies on TRAF6 and BSG to get molecular level insights of the reactions. PMID: 28612997 miR-146a suppresses the inflammatory response in human white adipocytes via targeting the expression of IRAK1 and TRAF6. PMID: 27922090 miRNA146a expression was significantly higher in hepatitis C patients with a best cut off value 1.63 to discriminate between hepatitis C patients and healthy controls. Meanwhile, it was negatively correlated to IRAK1 and TRAF6 levels and positively correlated to viral load in hepatitis C patients. PMID: 28587864 Suggest role for EBV-EBER1 in the induction of increased TRAF6 expression in the peripheral B cells of Sjogren's patients. PMID: 28470929 theses results indicate that miR-146b-5p inhibits tumor growth and metastasis of hepatocellular carcinoma by targeting TRAF6 mediated Akt phosphorylation PMID: 28404923 TRAF6 plays direct roles in the pro-inflammatory effects and proliferation of Rheumatoid arthritis (RA) fibroblast-like synoviocytes. TRAF6 may serve as a potential treatment target in RA. PMID: 28506571 MiR-146a declined, while TRAF6 increased in lupus nephritis patients compared with healthy controls. PMID: 28549054 Epigallocatechin-3-gallate is a novel E3 ubiquitin ligase inhibitor that could be used to target TRAF6 activity in melanoma cells, inhibiting cell proliferation/migration. PMID: 27791197 Results identified TRAF6 as a direct target of miR-429, and its downregulation partially attenuates the effect of miR-429 in promoting hepatocellular carcinoma cell proliferation and motility. PMID: 28440423 Compared with normal chondrocytes, the expression of miR-146a decreased, while the mRNA and protein expressions of TRAF6 and NF-kappaB increased in osteoarthritis chondrocytes. PMID: 28314786 We report two siblings with SCID and an atypical phenotype of osteopetrosis (OP). A biallelic microdeletion encompassing the 5' region of TRAF6, RAG1 and RAG2 genes was identified. TRAF6, a tumor necrosis factor receptor-associated family member, plays an important role in T cell signaling and in RANKL-dependent osteoclast differentiation and activation but its role in human OP has not been previously reported PMID: 27808398 Taken together, these results define a novel role for miR-146a as a negative regulator of dengue virus-induced autophagy and identify TRAF6 as a key target of this microRNA in modulating the dengue virus-autophagy interaction. PMID: 28825144 These data define that YOD1 antagonizes TRAF6/p62-dependent IL-1 signaling to NF-kappaB. PMID: 28244869 high expression of TRAF6 is significant for esophageal cancer progression, and TRAF6 indicates poor prognosis in esophageal cancer patients. PMID: 27697099 the polymorphisms in TLR-MyD88-NF-kappaB signaling pathway confer genetic susceptibility to Type 2 diabetes mellitus and diabetic nephropathy. PMID: 27062898 The E3 ligase TRAF6 binds to DCP1a and indirectly regulates DCP1a phosphorylation, expression of decapping factors, and gene-specific mRNA decay. PMID: 27315556 Study showed that patients without a history of atrial fibrillation who develop postoperative atrial fibrillation have a higher percentage of left atrial fibrosis, increased expression of TRAF6, higher serum Ang II levels, and changes in the activities of the MAPKs/TGF-beta1/TRAF6 pathway. PMID: 28323847 Low TRAF6 expression is associated with graft-versus-host disease. PMID: 27485827 Consistent with cellular studies, icaritin downregulated TRAF6 and NFATc1 protein expression in CD11b(+) /Gr-1(-/low) osteoclast precursors PMID: 27813153 Results suggest that overexpression of miR-146a could promote IDD through the TRAF/NF-kappaB pathway. PMID: 28161709 TRAF6 and H2AX overexpression and gammaH2AX-mediated HIF1alpha enrichment in the nucleus of cancer cells lead to overactivation of HIF1alpha-driven tumorigenesis, glycolysis and metastasis. PMID: 27918549 These findings show that SopB suppresses host cell apoptosis by binding to TRAF6 and preventing mitochondrial reactive oxygen species generation. PMID: 27473656 HCV infection suppressed the host innate immune response through the induction of autophagic degradation of TRAF6. This finding provided important information for further understanding how HCV evades host immunity to establish persistence PMID: 27681126 Vav3 is a novel TRAF6 interaction partner that functions in the activation of cooperative signaling between T6BSs and the IVVY motif in the RANK signaling complex. PMID: 27507811 TRAF6 expression was decreased in tympanic membrane of otitis media patients. PMID: 27497395 Peripheral blood levels of S100A8 and TRAF6 in SAE patients were elevated and might be related to the severity of SAE and predict the outcome of SAE. PMID: 27411454 Low TRAF6 expression is associated with Graves' disease. PMID: 28219358 MiR-146a regulates inflammatory macrophage infiltration in Polymyositis/Dermatomyositis by targeting TRAF6 and affecting the IL-17/ICAM-1 pathway. PMID: 27889748 Study demonstrates that TRAF6 is upregulated in human lung cancer cells, and siRNA-induced TRAF6 knockdown inhibits the invasion of lung cancer cells and promotes apoptosis. PMID: 26847475 High TRAF6 expression is associated with melanoma invasion and metastasis. PMID: 26769849 The expression of TRAF6 was positively correlated with an advanced N stage and acted as a predictor of a poor prognosis in patients with gastric cancer PMID: 26627263 DAT stabilized IkBa by inhibiting the phosphorylation of Ika by the IkB kinase (IKK) complex. DAT induced proteasomal degradation of TRAF6, and DAT suppressed IKKb-phosphorylation through downregulation of TRAF6 PMID: 26647777 TRAF6 may be involved in cell migration, invasion, and apoptosis of SPC-A-1 cells, possibly through regulating the NF-B-CD24/CXCR4 pathway.. PMID: 26582220 In 816 matched pairs of Han Chinese with and without ischemic stroke, TRAF6 rs5030416 was associated with increased susceptibility in various genetic models. No association was found for rs5030411, although it was associated with total cholesterol. PMID: 25999280 Identify miR-146b-5p as a tumor suppressor and novel prognostic biomarker of gliomas, and suggest miR-146b-5p and TRAF6 as potential therapeutic candidates for malignant gliomas. PMID: 26320176 miR146a has an important promoting effect on the apoptosis of granulosa cells by targeting IRAK1 and TRAF6 via the caspase cascade pathway PMID: 26151128 Findings show that TRAF6 is involved in regulating HUVECs proliferation after intermittent hypoxia by modulating cell signaling downstream of AT1R which can be helpful in treating cardiovascular disorders for instance. PMID: 26223916 These findings suggest that TRAF6 is required for BLyS-mediated NF-kappaB signaling in myeloma cells PMID: 26334396 TIFAB loss increases TRAF6 protein and the dynamic range of TLR4 signaling PMID: 26458771 Transmembrane motif T6BM2-mediated TRAF6 binding is required for MAVS-related antiviral response. PMID: 26385923

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.